Article Details

AstraZeneca, Swiss firm Neurimmune ink $760 mln deal for antibody drug | Reuters

Retrieved on: 2022-03-01 09:08:06

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca, Swiss firm Neurimmune ink $760 mln deal for antibody drug | Reuters. View article details on HISWAI: https://www.reuters.com/world/uk/astrazeneca-inks-760-mln-deal-with-swiss-firm-neurimmune-antibody-drug-2022-03-01/

Excerpt

Anglo-Swedish drugmaker AstraZeneca, which made a $39 billion bet on Alexion's rare diseases portfolio in 2020, has had major success with monoclonal ...

Article found on: www.reuters.com

View Original Article

This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up